ABT Stock Recent News

This morning, we see a new print on international trade as well as further articulation on Q3 earnings, particularly in banking/finance and Big Pharma. Pre-market futures are slightly up at this hour: the Dow +22 points, the S&P 500 +1 and the Nasdaq +5 points.

I reiterate a “Strong Buy” rating for Abbott Laboratories with a fair value of $135 per share due to their strong R&D pipeline and robust financial performance. Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals, leading to raised full-year EPS guidance. Despite ongoing NEC baby formula lawsuits, the financial impact is marginal, representing only 0.02% of total revenue.

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 20 points on Wednesday.

Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company's medical-devices business.

Sales of $10.6 billion driven by strong underlying base business performance Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical Devices Continues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical data ABBOTT PARK, Ill., Oct. 16, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.

Abbott Laboratories ABT will release earnings results for its third quarter, before the opening bell on Wednesday, Oct. 16.

#Morningstar  #ValueStocks #StockInvesting As value stocks rebound, here's where the smart money is investing. 00:00 Introduction 00:40 CVS CVS 01:39 Abbott ABT 02:26 Equifax EFX Susan Dziubsinki: I'm Susan Dziubinski with Morningstar.

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Abbott (NYSE: ABT) will report its Q3 2024 results on Wednesday, Oct 16. We expect the company to post revenue of $10.6 billion and earnings of $1.20 on a per share and adjusted basis, aligning with the street expectations.

Evaluate the expected performance of Abbott (ABT) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.